Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Asuragen to Collaborate on Companion Diagnostics Development

NEW YORK (GenomeWeb) – Illumina and Asuragen plan to collaborate on companion diagnostics development, Asuragen said today.

Under the agreement, Asuragen will leverage its Quantidex next-generation sequencing product platform and Illumina's MiSeq Dx instrument, which has US Food and Drug Administration 510(k) clearance, to develop customized companion diagnostics for its biotech and pharmaceutical partners.

The Quantidex DNA assay is a multiplexed quantitative PCR assay that measures the absolute copy number of PCR-amplifiable DNA in a sample, according to Asuaragen. In addition, the firm recently launched its Quantidex Pan Cancer kit,  a research-use-only product that analyzes 46 amplicons from 21 genes.

President and CEO of Asuragen Matt McManus said in a statement that the firm's Quantidex NGS product platform would enable pharmaceutical and biotech companies to develop "a unique DNA and/or RNA panel of interest." In addition, he said, the system is "built under design control and manufactured in our cGMP facility, providing a high-quality basis for regulated diagnostic product development."

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.